Abstract
The clinical outlook for adults with acute lymphoblastic leukemia (ALL) has improved with the use of intensive chemotherapy. Complete remissions (CR) are achieved in 80% of adults but the majority relapse on maintenance chemotherapy and a few exhibit primary resistance to induction therapy. This report compares the various salvage treatments and provides guidance in selecting a regimen with the optimum clinical outcome. Regimens using high- dose ara-C (HDAC) in combination with mitoxantrone, amsacrine, or idarubicin are superior to HDAC alone or with L-asparaginase. The sequential administration of methotrexate and L-asparaginase is equally effective. The duration of second CR is short for all chemotherapeutic regimens.
Original language | English (US) |
---|---|
Pages (from-to) | 341-344 |
Number of pages | 4 |
Journal | American Journal of Hematology |
Volume | 45 |
Issue number | 4 |
State | Published - 1994 |
Keywords
- acute lymphoblastic leukemia
- reinduction regimens
- remission
- treatment
ASJC Scopus subject areas
- Hematology